Patents by Inventor Iwao Ojima

Iwao Ojima has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250009658
    Abstract: A composition of an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate encapsulated in an oil-in-water nanoemulsion (NE) drug delivery system. A method of treating cancer by administering an effective amount of a pharmaceutical composition including a PUFA-taxoid conjugate encapsulated in an oil-in-water NE drug delivery system to a subject in need of treatment, and treating cancer. A method of overcoming multidrug resistance by exposing a multidrug resistant cell to an effective amount of a pharmaceutical composition including an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate encapsulated in an oil-in-water NE drug delivery system, and inducing the death of the multidrug resistant cell. A method of eliminating a cancer stem cell. Methods of reducing stemness of a cancer stem cell, retaining drug in the body, and providing a slower release profile.
    Type: Application
    Filed: July 16, 2024
    Publication date: January 9, 2025
    Applicants: TargaGenix, Inc., Research Foundation for State University New York, Northeastern University
    Inventors: James E. EGAN, Iwao OJIMA, Mansoor M. AMIJI, Galina Ivanovna BOTCHKINA
  • Patent number: 12186428
    Abstract: A composition of an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate formulated in an oil-in-water nanoemulsion (NE) drug delivery system in combination with an immune-oncology (IO) agent to enhance therapeutic efficacy in refractory cancers, such as PDAC. A method of treating cancer, by administering an effective amount of a pharmaceutical composition including an omega03 PUFA-taxoid conjugate in combination with an IO agent encapsulated in an NE drug delivery system to a subject in need of treatment, and treating cancer.
    Type: Grant
    Filed: November 14, 2022
    Date of Patent: January 7, 2025
    Assignees: TargaGenix, Inc., The Research Foundation for the State University of New York, Northeastern University
    Inventors: James E. Egan, Mansoor M. Amiji, Iwao Ojima
  • Publication number: 20240336559
    Abstract: The present invention provides a compound having the structure: wherein R3, R4, R5, R6, and R7 are each independently, H, halogen, CN, —CF3, —OCF3, —NO2, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocycle, —OH, —OAc, —OR13, —COR13, —CH2OR13, —SH, —SR13, —SO2R13, —NH2, —NHR13, —NR14R15, —NHCOR12, or —CONR14R15; R9, R10, R11, and R12 are each independently, H, CN, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —OAc, —COR13, —SH, —SR13, —SO2R13, —NH2, —NHR13, —NR14R15, —NHCOR12, or —CONR14R15; wherein each occurrence of R13 is independently alkyl, alkenyl, alkynyl, aryl, or heteroaryl, wherein each occurrence of R14 is independently —H, alkyl, alkenyl, alkynyl, aryl, or heteroaryl, wherein each occurrence of R15 is independently —H, alkyl, alkenyl, alkynyl, aryl, or heteroaryl, wherein when R14 is methyl, R15 is not methyl; wherein at least one of R9, R10, R11, and R12 is not H; wherein at least one of R3, R4, R5, R6, and R7 is not H.
    Type: Application
    Filed: October 6, 2022
    Publication date: October 10, 2024
    Applicant: The Research Foundation for the State University of New York
    Inventors: Iwao Ojima, Krupanandan HARANAHALLI, Maurizio DEL POETA, Ashna GARG
  • Patent number: 12018003
    Abstract: The invention relates to substituted pyrimidine compounds with the following formula: or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof. These compounds selectively target the hemopexin domain of matrix metalloproteinase 9 (MMP-9) and do not inhibit the protease's catalytic functions. The invention also relates to methods of treating cancer in a patient in need thereof with the compounds.
    Type: Grant
    Filed: June 21, 2021
    Date of Patent: June 25, 2024
    Assignee: The Research Foundation for The State University of New York
    Inventors: Iwao Ojima, Vincent Alford, Anushree Kamath, Jian Cao, Xiadong Ren, Nicole Sampson, Monaf Awwa
  • Publication number: 20240124392
    Abstract: The present invention provides a compound having the structure: and use of the compound for inhibiting the growth of or killing
    Type: Application
    Filed: December 6, 2023
    Publication date: April 18, 2024
    Applicant: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Iwao Ojima, Maurizio Del Poeta, Cristina Lazzarini, Krupanandan Haramahalli, Yi Sun
  • Publication number: 20240092725
    Abstract: The present invention provides a compound, and method of inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with a compound, said compound having the structure: Formula
    Type: Application
    Filed: July 3, 2023
    Publication date: March 21, 2024
    Applicant: The Research Foundation for the State University of New York
    Inventors: Iwao Ojima, Dale Deutsch, Martin Kaczocha, Kongzhen Hu, Simon Tong, Matthew Elmes, Su Yan
  • Patent number: 11858880
    Abstract: The present invention provides a compound having the structure: and use of the compound for inhibiting the growth of or killing
    Type: Grant
    Filed: June 10, 2022
    Date of Patent: January 2, 2024
    Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Iwao Ojima, Maurizio Del Poeta, Cristina Lazzarini, Krupanandan Hanarahalli, Yi Sun
  • Publication number: 20230365488
    Abstract: The present invention provides a compound, and method of selectively inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with a compound, said compound having the structure:
    Type: Application
    Filed: October 8, 2021
    Publication date: November 16, 2023
    Applicant: The Research Foundation for The State University of New York
    Inventors: Iwao Ojima, Martin Kaczocha, Monaf Awwa, Antonella Pepe
  • Patent number: 11739047
    Abstract: The present invention provides a compound, and method of inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with a compound, said compound having the structure: Formula (I)
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: August 29, 2023
    Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Iwao Ojima, Dale Deutsch, Martin Kaczocha, Kongzhen Hu, Simon Tong, Matthew Elmes, Su Yan
  • Publication number: 20230082272
    Abstract: A composition of an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate formulated in an oil-in-water nanoemulsion (NE) drug delivery system in combination with an immune-oncology (IO) agent to enhance therapeutic efficacy in refractory cancers, such as PDAC. A method of treating cancer, by administering an effective amount of a pharmaceutical composition including an omega03 PUFA-taxoid conjugate in combination with an IO agent encapsulated in an NE drug delivery system to a subject in need of treatment, and treating cancer.
    Type: Application
    Filed: November 14, 2022
    Publication date: March 16, 2023
    Applicants: TargaGenix, Inc., The Research Foundation for the State University of New York, Northeastern University
    Inventors: James E. EGAN, Mansoor M. AMIJI, Iwao OJIMA
  • Publication number: 20230017948
    Abstract: This invention provides a method of treating a subject afflicted with a cancer comprising periodically administering to the subject an amount of a FABP5 inhibitor and an amount of an anticancer therapy, wherein the amounts when taken together are effective to treat the subject. This invention also provides FABP5 inhibitors for use as an add-on therapy or in combination with an anticancer therapy or in treating a subject afflicted with a cancer. This invention also provides the use of a FABP5 inhibitor in the manufacturing of a medicament for use in combination or as an add on with an anticancer therapy in treating a subject afflicted with cancer, wherein the FABP5 inhibitor and the anticancer therapy are administered simultaneously, contemporaneously or concomitantly.
    Type: Application
    Filed: November 24, 2020
    Publication date: January 19, 2023
    Applicant: The Research Foundation for The State University of New York
    Inventors: Iwao Ojima, Martin Kaczocha, Gregory Carbonetti
  • Publication number: 20220394973
    Abstract: The present invention provides a compound having the structure: and use of the compound for inhibiting the growth of or killing
    Type: Application
    Filed: June 10, 2022
    Publication date: December 15, 2022
    Applicant: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Iwao Ojima, Maurizio Del Poeta, Cristina Lazzarini, Krupanandan Haranahalli, Yi Sun
  • Patent number: 11497713
    Abstract: A composition of an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate formulated in an oil-in-water nanoemulsion (NE) drug delivery system in combination with an immune-oncology (IO) agent to enhance therapeutic efficacy in refractory cancers, such as PDAC. A method of treating cancer, by administering an effective amount of a pharmaceutical composition including an omega03 PUFA-taxoid conjugate in combination with an IO agent encapsulated in an NE drug delivery system to a subject in need of treatment, and treating cancer.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: November 15, 2022
    Assignees: TargaGenix, Inc., The Research Foundation for The State University of New York, Northeastern University
    Inventors: James E. Egan, Mansoor Amiji, Iwao Ojima
  • Patent number: 11414378
    Abstract: The present invention provides a compound having the structure: and use of the compound for inhibiting the growth of or killing a fungus.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: August 16, 2022
    Assignee: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: Iwao Ojima, Maurizio Del Poeta, Cristina Lazzarini, Krupanandan Haranahalli, Yi Sun
  • Publication number: 20210309616
    Abstract: Small molecule inhibitors are claimed that selectively target the hemopexin domain of matrix metalloproteinase 9 (MMP-9) and do not inhibit the protease's catalytic functions. A method of treating cancer in a patient in need thereof with the compounds of the invention is also claimed.
    Type: Application
    Filed: June 21, 2021
    Publication date: October 7, 2021
    Inventors: Iwao OJIMA, Vincent ALFORD, Anushree KAMATH, Jian CAO, Xiadong REN, Nicole SAMPSON, Monaf AWWA
  • Patent number: 11040947
    Abstract: A compound of Formula I: wherein: Y is —C(O)NHR1 or —NHC(O)R1; R1 is aryl; ?is ?optionally substituted with one or more substituents selected from the group consisting of oxo, F, Cl, Br, I, alkyl, NH2, NHR4, NHC(O)R4, NHC(O)OR4, NR5R6, OH, OR4, SR4, cycloalkyl and aryl; or ?is ?optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, NO2, alkyl, C(O)R4, C(O)NHR4, C(O)NR5R6, C(O)OH, C(O)OR4, NH2, NHR4, NHC(O)OR4, NR5R6, OH, OR4, SR4, cycloalkyl and aryl; each R4 is independently alkyl, cycloalkyl, or aryl; each R5 is independently alkyl, cycloalkyl, or aryl; each R6 is independently alkyl, cycloalkyl, or aryl; or each R5 and R6, together with the nitrogen atom to which they are attached, independently form an unsubstituted heterocyclic alkyl or unsubstituted heterocyclic aryl; and X is —S— or —O—; and n is 2, 3, or 4.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: June 22, 2021
    Assignee: The Research Foundation for The State University of New York
    Inventors: Iwao Ojima, Vincent Alford, Anushree Kamath, Jian Cao, Xiadong Ren, Nicole Sampson, Monaf Awwa
  • Publication number: 20210179535
    Abstract: The present invention provides a compound, and method of inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with a compound, said compound having the structure: Formula (I)
    Type: Application
    Filed: February 11, 2021
    Publication date: June 17, 2021
    Applicant: The Research Foundation for The State University of New York
    Inventors: Iwao Ojima, Dale Deutsch, Martin Kaczocha, Kongzhen Hu, Simon Tong, Matthew Elmes, Su Yan
  • Patent number: 11026910
    Abstract: The present invention provides a compound, and method of inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with a compound, having the structure:
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: June 8, 2021
    Assignee: The Research Foundation for The State University of New York
    Inventors: Iwao Ojima, Dale Deutsch, Martin Kaczocha, William T. Berger, Robert Rizzo, Trent E. Balius
  • Patent number: 10968163
    Abstract: The present invention provides a compound, and method of inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with a compound, said compound having the structure: Formula (I).
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: April 6, 2021
    Assignee: The Research Foundation for the State University of New York
    Inventors: Iwao Ojima, Dale Deutsch, Martin Kaczocha, Kongzhen Hu, Simon Tong, Matthew Elmes, Su Yan
  • Patent number: RE50096
    Abstract: A composition of an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate encapsulated in an oil-in-water nanoemulsion (NE) drug delivery system. A method of treating cancer by administering an effective amount of a pharmaceutical composition including a PUFA-taxoid conjugate encapsulated in an oil-in-water NE drug delivery system to a subject in need of treatment, and treating cancer. A method of overcoming multidrug resistance by exposing a multidrug resistant cell to an effective amount of a pharmaceutical composition including an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate encapsulated in an oil-in-water NE drug delivery system, and inducing the death of the multidrug resistant cell. A method of eliminating a cancer stem cell. Methods of reducing stemness of a cancer stem cell, retaining drug in the body, and providing a slower release profile.
    Type: Grant
    Filed: February 19, 2021
    Date of Patent: August 27, 2024
    Assignees: Targagenix, Inc., Northeastern University
    Inventors: James E. Egan, Iwao Ojima, Mansoor M. Amiji, Galina Ivanovna Botchkina